NeuroSense Therapeutics Warrant
NRSNW
5 hedge funds and large institutions have $59K invested in NeuroSense Therapeutics Warrant in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.67% less ownership
Funds ownership: 2.9% → 2.23% (-0.67%)
45% less capital invested
Capital invested by funds: $107K → $59K (-$48.1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.68K |
| 2 |
CS
Clear Street
New York
|
+$630 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$32 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$19.6K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$18 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Hudson Bay Capital Management
Stamford,
Connecticut
| $20.7K | -$19.6K | -62,266 | -42% |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $15.4K | -$18 | -56 | -0.1% |
|
|
CS
3
Clear Street
New York
| $13.9K | +$630 | +2,001 | +4% |
|
|
4
Citadel Advisors
Miami,
Florida
| $8.96K | +$1.68K | +5,323 | +16% |
|
|
5
Bank of America
Charlotte,
North Carolina
| $16 | +$32 | +100 | New |
|
NRSNW Hedge Fund Activity: Q2 2023 in Review
5 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q2 2023, worth a combined $59K — down 45% from $107K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new NRSNW positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $1.68K. The largest seller was Hudson Bay Capital Management, cutting an estimated $19.6K.
- 5 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q2 2023, up from 4 in Q1 2023.
- Funds reported $59K of NeuroSense Therapeutics Warrant stock for Q2 2023, down 45% quarter-over-quarter.
- 1 fund opened new NeuroSense Therapeutics Warrant positions in Q2 2023 and 0 closed out, a net change of +1 holder.
- The largest NeuroSense Therapeutics Warrant buyer in Q2 2023 was Citadel Advisors, an estimated $1.68K added.
- The largest NeuroSense Therapeutics Warrant seller in Q2 2023 was Hudson Bay Capital Management, an estimated $19.6K sold.
Based on aggregated 13F filings for Q2 2023.